Severe heart valve disease on appetite suppressants.
D000328:Adult; D001067:Appetite Depressants / Q000009:adverse effects; D016022:Case-Control Studies; D004053:Diethylpropion / Q000009:adverse effects; D017277:Drug Approval; D004338:Drug Combinations; D005060:Europe; D005260:Female; D005277:Fenfluramine / Q000009:adverse effects*; D006349:Heart Valve Diseases / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000503:physiopathology; D006801:Humans; D006976:Hypertension, Pulmonary / Q000139:chemically induced*; D008297:Male; D008694:Methamphetamine / Q000009:adverse effects / Q000031:analogs & derivatives; D009765:Obesity / Q000188:drug therapy*; D010633:Phenmetrazine / Q000009:adverse effects; D010645:Phentermine / Q000009:adverse effects*; D016896:Treatment Outcome; D014463:Ultrasonography; D014481:United States; D014486:United States Food and Drug Administration
D001067:Appetite Depressants; D004338:Drug Combinations; D005277:Fenfluramine; D008694:Methamphetamine; D010645:Phentermine; D004053:Diethylpropion; D010633:Phenmetrazine